LIGAND PHARMACEUTICALS INC 8-K

What Happened

• On June 22, 2026, Ligand Pharmaceuticals Inc. announced a proposed private placement of $550 million aggregate principal amount of convertible senior notes due 2031 (the "Notes") to qualified institutional buyers under Rule 144A. The initial purchasers have a 13‑day option to buy up to an additional $82.5 million of Notes.
• The company also entered into a Consent and Fourth Amendment to its Credit Agreement (the "Fourth Amendment") on June 22, 2026 to permit issuance of the Notes and to modify certain covenant testing levels.

Key Details

• Offering size: $550,000,000 aggregate principal amount, plus an initial purchasers' option for up to $82,500,000.
• Note maturity: 2031 (convertible senior notes).
• Credit amendment: Fourth Amendment to the Credit Agreement (originally dated Oct 12, 2023) executed June 22, 2026 with Citibank, N.A. as Administrative Agent.
• Covenant change: minimum Consolidated EBITDA requirement set at $100,000,000 for each four-quarter period ending June 30, 2026; Sept 30, 2026; Dec 31, 2026; and Mar 31, 2027, and $150,000,000 for each four-quarter period thereafter.

Why It Matters

• The Notes would increase Ligand’s indebtedness and could dilute existing shareholders if the notes are converted into equity; terms of conversion were not included in the 8‑K. The private placement to qualified institutional buyers indicates the company is raising capital from institutional investors rather than a public offering.
• The Fourth Amendment explicitly permits the Notes issuance and adjusts the EBITDA covenant levels, which affects the company’s financial covenant tests and flexibility under its credit facilities. Investors should watch subsequent disclosures for final pricing, interest/coupon, conversion mechanics, and any impact on leverage or liquidity.